ia_64/iStock via Getty Images Shares of ophthalmology-focused specialty pharmaceutical concern Harrow, Inc. (NASDAQ:HROW) are down some 45% since their highs in the spring of 2023. However, they seem likely to rebound as the market starts to look at the potential for Iheezo. Its launch and that of dry eye therapy Vevye suggest that the company's FY24 net revenue outlook of $180 million plus might be very conservative. In addition, the recent insider and beneficial owner buying also merited a deeper dive. Se ...